Rossari Biotech

ROSSARI: New Expansion Projects Will Drive Global Market Penetration

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Feb 25

Updated

06 Dec 25

Views

53

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-28.5%

7D

-2.1%

Loading

1Y

-28.5%

7D

-2.1%

You can edit this narrative until Dec 7 11:05 PM. Then, changes will post as Updates.

Author's Valuation

₹795.7528.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 06 Dec 25

ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside

Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.

Shared on 22 Nov 25

ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead

Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.

Shared on 04 Nov 25

Fair value Decreased 3.74%

Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).

Shared on 01 May 25

Fair value Decreased 12%

Shared on 23 Apr 25

Fair value Decreased 0.27%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 5.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Increased 4.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹795.75

28.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

14.61%

Chemicals revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

13.65%

Calculation

₹2.52b

Earnings '28

x

25.48x

PE Ratio '28

=

₹64.21b

Market Cap '28

₹64.21b

Market Cap '28

/

55.50m

No. shares '28

=

₹1.16k

Share Price '28

₹1.16k Share Price '28

Discounted to 2025 @ 13.63% p.a.

=

₹788.60

Fair Value '25